Worldwide, iron deficiency anemia (IDA) is the most common nutritional deficiency,
and its management remains a challenge in many cases.(OIT)Oral iron therapy, in appropriate
doses and for a sufficient duration, is an effective first-line strategy
for most patients.
But some patients do not experiencean optimal response to(OIT).The need is still
current and clinically relevant for predictors of response to OIT. Hepcidin-25, a major regulator
of iron metabolism, may be use as a reliable guide for the use of iron and be one of
them.112 patientswith IDA were enrolled in this follow up clinical trial, Selected from two
university, hospitals in Damascus between JUNE2015 and JUNE2016. For patients who
met the inclusion criteria, Baseline CBC, iron studies, and serum hepcidin-25 were measured,
and then they received a 14-day course of oral iron (ferrous gluconate 325mg/ 3 times
daily). Patients who achieved <1g/dl increase in Hb in 14 days were categorized as “nonresponders”.
Screening hepcidin levels were (40.18± 86.35) versus (6.37±10.37)(p=
0.041(innonresponders versus responders to oral iron trial. HepcidinCutoff of >14.3 ng/ml,
showed sensitivity of 40%,specificity of 90.2%, andpositive predictive value of 60% andnegative
predictive value of 80% for predicting nonresponsiveness to oral iron.We conclude
that serum hepcidin25predicts poorly nonresponsivenesstooral iron therapy in IDA
patients, but it is superior to ferritin and TSAT for this purpose.
